Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
94 Leser
Artikel bewerten:
(0)

MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition

GAITHERSBURG, Md., Nov. 16 /PRNewswire/ -- MedImmune today announced the winners of a research abstract competition highlighting the work of the next generation of scientific leaders in respiratory disease, inflammation and autoimmunity (RIA). Students and postdoctoral fellows from across the country were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, a leading biologics company headquartered in Gaithersburg, Maryland.

The competition's ten finalists convened today at the company's headquarters to present their research to an expert panel of MedImmune judges. The three winners were announced at the awards ceremony following the presentations.

First prize of $2,000 was awarded to Eric Boilard, a postdoctoral student of Harvard Medical School and Brigham & Women's Hospital for his research on the role of platelets in amplifying inflammation in arthritis. "I would like to thank everyone at MedImmune for sponsoring this competition. I am honored to be a winner and grateful for the opportunity to receive such great feedback from renowned individuals on the panel."

Second and third prizes of $1,000 and $500 were awarded to Irving Allen of University of North Carolina and Kerstin Kiefer of Boston University School of Medicine, respectively.

"We saw some very high-caliber preclinical approaches," said Anthony J. Coyle, Ph.D., vice president, research and development and head, respiratory, inflammation and autoimmunity research at MedImmune. "Their research could pave the way for further understanding of the mechanism of these diseases, and could potentially help in the development of new therapies."

"We are committed to investing in future scientists and promoting health and science education," said Bahija Jallal, Senior Vice President of Research and Development at MedImmune. "We were impressed with today's presentations, and congratulate all of the ten finalists on their thought-provoking work."

The competition was open to graduate students and postdoctoral fellows worldwide. The expert panel of judges evaluated the abstracts according to the following criteria: scientific rationale, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

Notes to Editors: First Place: Harvard Medical School, Brigham & Women's Hospital postdoctoral student Eric Boilard. The title of his abstract is "Platelets amplify inflammation in arthritis via collagen-dependent microparticle production." Second Place: University of North Carolina at Chapel Hill postdoctoral student Irving Allen. The title of his abstract is "NLRX1 is a regulator of the innate immune response to influenza A virus infection." Third Place: Boston University School of Medicine postdoctoral student Kerstin Kiefer. The title of her abstract is "The role of TAM receptor tyrosine kinases in B cell activation and differentiation." About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC , has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at http://www.medimmune.com/.

Media Contact: Perla Copernik (301) 398-4952

MedImmune

CONTACT: Perla Copernik, +1-301-398-4952, for MedImmune

Web Site: http://www.medimmune.com/

© 2009 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.